Test Price
1,000 AED✅ Home Collection Available
JAK2 Exon 12 Mutation Detection Test in UAE | 1000 AED | DHA Compliant
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
Telephonic Post-Test Clinical Guidance in Result Interpretation
Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The JAK2 Exon 12 Mutation Detection Test identifies insertions, deletions, and point mutations in exon 12 of the JAK2 gene, essential for diagnosing polycythemia vera and other myeloproliferative neoplasms in patients negative for the common V617F mutation. Using PCR and fragment analysis, this test delivers DHA‑compliant precision and results within 3–4 days.
| Feature | Our Test (JAK2 Exon 12 Fragment Analysis) | Closest Alternative (JAK2 V617F PCR) |
|---|---|---|
| Mutation Coverage | Exon 12 insertions, deletions, point mutations | V617F point mutation only |
| Methodology | PCR + Fragment & STR Analysis | PCR-RFLP / Allele-Specific PCR |
| Turnaround Time | 3–4 days (Sample Mon/Thu by 11 am; Report Wed/Sat) | 2–3 days |
| Price (AED) | 1000 | ~800 |
| Clinical Significance | Essential for V617F-negative polycythemia vera workup | High prevalence but misses ~3% of PV cases |
Physician Insight & Safety Protocols
“A positive JAK2 exon 12 mutation detection is highly specific for polycythemia vera in patients without V617F. However, negative results do not rule out myeloproliferative neoplasms; comprehensive clinical and bone marrow evaluation is essential. Always consult a specialist for interpretation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. Any alteration to therapy must be based on clinical correlation and specialist guidance.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: None specific; however, patients on anticoagulants may experience increased bruising. Minors (<18 years) require DHA‑compliant guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags (Seek immediate ER care): Sudden severe headache, visual disturbances, chest pain, shortness of breath, or signs of thrombosis (swelling, redness in limbs) – these could indicate thrombotic events related to underlying myeloproliferative neoplasm. This test is not a substitute for emergency medical evaluation.
Patient FAQ & Clinical Guidance
1. What is the purpose of the JAK2 exon 12 mutation test?
This test detects specific exon 12 mutations in the JAK2 gene that cause polycythemia vera when V617F is absent. It uses PCR amplification and fragment analysis to identify insertions, deletions, or point mutations that lead to uncontrolled blood cell production. The result helps confirm a diagnosis of polycythemia vera, essential thrombocythemia, or primary myelofibrosis in patients with suggestive clinical features.
2. How is the sample collected and prepared?
No special preparation is needed; the test requires 3 mL of whole blood collected in an EDTA lavender‑top tube. The sample must be kept refrigerated and never frozen. A completed Genomics Clinical Information Requisition Form (Form 20) is mandatory for processing. Our home collection service ensures proper handling and cold-chain transport directly to the ISO‑certified lab.
3. When are results available and how are they interpreted?
Results are reported within 3–4 days; sample collection on Mon/Thu by 11 am yields reports on Wed/Sat. A positive result indicates a clonal mutation in the JAK2 exon 12 region, strongly supporting a myeloproliferative neoplasm diagnosis. A negative result significantly reduces the likelihood of polycythemia vera but does not exclude other myeloid disorders. All results include telephonic clinical guidance to discuss implications with a specialist.
UAE Regulatory & Data Privacy Adherence
All diagnostic data is processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your privacy and health information security are our priority.
Clinical & Logistical Metadata
| Test Name | JAK2 Exon 12 Mutation Detection |
| Price (AED) | 1000 |
| Turnaround Time | 3–4 days (Sample Mon/Thu by 11 am; Report Wed/Sat) |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA Lavender-Top Tube) |
| Methodology Used | PCR & Fragment Analysis |
| ICD-10-CM Code | D45 |
| LOINC Code | 92735-6 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians